PAC - Research Findings

The Patient’s Perspective on the Effects of Intranasal Esketamine in Treatment-Resistant Depression

Read paper

Condition Treated :

Depression

Psychedelic Medicine :

Ketamine

Keywords

Esketamine Nasal Spray versus Quetiapine for Treatment-Resistant Depression

Read paper

Condition Treated :

Depression

Psychedelic Medicine :

Ketamine

Keywords

Psilocybin-assisted therapy for depression: A systematic review and meta-analysis

Read paper

Condition Treated :

Depression

Psychedelic Medicine :

Psilocybin

Keywords

Therapeutic Potential of Psilocybin for Treating Psychological Distress among Survivors of Adverse Childhood Experiences: Evidence on Acceptability and Potential Efficacy of Psilocybin Use

Read paper

Condition Treated :

Anxiety

Psychedelic Medicine :

Psilocybin

Keywords

Longitudinal associations between psychedelic use and meditation practices in the United States and the United Kingdom

Read paper

Condition Treated :

N/A; Healthy volunteers

Psychedelic Medicine :

Other

Keywords

Adults who microdose psychedelics report health related motivations and lower levels of anxiety and depression compared to non-microdosers

Read paper

Condition Treated :

Anxiety

Psychedelic Medicine :

Psilocybin

Keywords

Vitamin C, Pain and Opioid Use Disorder

Read paper

Condition Treated :

Psychedelic Medicine :

Other

75% of heroin users in treatment report that their opioid misuse began with the use of legal prescription painkillers

The practices of healthcare providers are implicated in the spread of heroin addiction

In an animal study, rats that were given ascorbic acid (AA; vitamin C) exhibited less responses to receive morphine than those rats who were not given AA. Furthermore, rats given AA showed less withdrawal symptoms once morphine was discontinued
In another animal study, mice pre-treated with AA were significantly less likely to develop tolerance and dependence on morphine (injected twice daily)
In guinea pigs, treatment with AA inhibited morphine withdrawal response

AA irreversibly inactivated opioid binding in guinea pig brain homogenate

Animals that have the ability to synthesize AA increase endogenous production of AA when experiencing disease, pain, and stress
Administration of AA is associated with better surgical outcomes
In one study, patients who received AA required significantly less morphine for pain management than those who received a placebo
In one study, administration of AA helped relieve fibrosarcoma-related pain
In one study, administration of AA helped relieve pain in breast cancer patients with skeletal metastases
In one study, administration of AA reduced opiate reliance in bladder cancer patients
In one study, it was found that AA administration reduced the risk of developing subsequent chronic regional pain syndrome in patients with recent wrist fracture
In one study, 57% of patients in the vitamin C and E group experienced significant reduction in withdrawal symptoms (of opioid use), whereas only 7% in control group reported the same
In another study of AA administration for opioid use disorder and withdrawal symptoms, one-third of 60 patients reported that 70% or more of acute withdrawal symptoms were gone, half reported at least 60% of symptoms were relieved, and aftercare clients reported a 90% relief of symptoms
Vitamin C (AA) can occupy specific opioid receptor sites and thus block their effect
In one study, sodium ascorbate ceased signs and symptoms of heroin withdrawal in all patients
Patients with major depressive disorder and drug addictions have low plasma AA levels
AA decreases oxidative stress

Anxiety, depression, bipolar disorder, panic disorder, obsessive-compulsive disorder, and schizophrenia are associated with oxidative stress
Antioxidants are important for mental health
People with mental health conditions (i.e. anxiety and/or depression) are three times more likely to use opioids than the general population

Highest concentrations of AA are found in the adrenal glands, thus vitamin C is part of the human stress response. In times of stress, AA stores are rapidly depleted, thus exogenous replacement of AA is crucial during times of stress
Low AA intake has been correlated with fatigability in humans
Vitamin C may support the endogenous synthesis of important neurotransmitters (dopamine, serotonin, and norepinephrine) and modulates dopamine and glutamate (important for off-setting addictive behaviours)

Keywords

vitamin C, opioid use disorder, pain, ascorbic acid, mental health, antioxidant, opioid withdrawal, mental health disorders

Medical Cannabis for Pediatric Moderate to Severe Complex Motor Disorders

Read paper

Condition Treated :

Complex Motor Disorder

Psychedelic Medicine :

Cannabis

Keywords

complex motor disorder, cannabidiol, CBD, tetrahydrocannabinol, THC

Evaluation of the effects of CBD hemp extract on opioid use and quality of life indicators in chronic pain patients: a prospective cohort study

Read paper

Condition Treated :

Chronic Pain

Psychedelic Medicine :

Cannabis

Keywords

pain, opioid use, cannabidiol, CBD, pain treatment, cannabidiol treatment, CBD treatment

The Effectiveness of Topical Cannabidiol Oil in Symptomatic Relief of Peripheral Neuropathy of the Lower Extremities

Read paper

Condition Treated :

Peripheral Neuropathy

Psychedelic Medicine :

Cannabis

Keywords

cannabidiol, CBD, peripheral neuropathy, peripheral nerve damage, pain, inflammation, CBD treatment, cannabidiol treatment

Salvia divinorum: from recreational hallucinogenic use to analgesic and anti-inflammatory action

Read paper

Condition Treated :

N/A; Healthy volunteers

Psychedelic Medicine :

Salvia Divinorum

Keywords

salvia divinorum, salvia

Antidepressant Effects of the Herb Salvia Divinorum: A Case Report

Read paper

Condition Treated :

Depression

Psychedelic Medicine :

Salvia Divinorum

Keywords

salvia divinorum, salvia, psychedelic treatment, plant medicine, depression, salvia treatment, treatment-resistant depression

The subjective experience of acute, experimentally-induced Salvia divinorum inebriation

Read paper

Condition Treated :

N/A; Healthy volunteers

Psychedelic Medicine :

Salvia Divinorum

Keywords

salvia divinorum, salvia, depression, addiction, substance use disorder

The Appeal of Peyote (Lophophora Williamsii) as a Medicine

Read paper

Condition Treated :

Substance Use Disorder

Psychedelic Medicine :

Mescaline

Keywords

peyote, mescaline, psychedelic treatment, peyote treatment, mescaline treatment, alcohol use disorder, substance use disorder

Psychological and Cognitive Effects of Long-Term Peyote Use Among Native Americans

Read paper

Condition Treated :

Substance Use Disorder

Psychedelic Medicine :

Mescaline

Keywords

peyote, mescaline, psychedelic treatment, peyote treatment, mescaline treatment, alcohol use disorder, substance use disorder, alcoholism

The non-hallucinogen 2-bromo-lysergic acid diethylamide as preventative treatment for cluster headache: an open, non-randomized case series

Read paper

Condition Treated :

Migraine

Psychedelic Medicine :

LSD

Keywords

LSD, lysergic acid diethylamide, BOL-148, cluster headache

Alterations in responses to LSD in humans associated with chronic administration of tricyclic antidepressants, monoamine oxidase inhibitors or lithium

Read paper

Condition Treated :

Antidepressant Use

Psychedelic Medicine :

LSD

Keywords

LSD, lysergic acid diethylamide, serotonin receptor, serotonin, dopamine, antidepressant, MAO, lithium, tricyclic antidepressant, subjective experience

The Fabric of Meaning and Subjective Effects in LSD-Induced States Depend on Serotonin 2A Receptor Activation

Read paper

Condition Treated :

N/A; Healthy volunteers

Psychedelic Medicine :

LSD

Keywords

LSD, lysergic acid diethylamide, serotonin receptor, self-relevance, meaningfulness

Role of the 5-HT 2A Receptor in Self- and Other-Initiated Social Interaction in Lysergic Acid Diethylamide-Induced States: A Pharmacological fMRI Study

Read paper

Condition Treated :

N/A; Healthy volunteers

Psychedelic Medicine :

LSD

Keywords

LSD, lysergic acid diethylamide, consciousness, default mode network, serotonin receptor, ego dissolution, self-reflection, posterior cingulate cortex

Changes in global and thalamic brain connectivity in LSD-induced altered states of consciousness are attributable to the 5-HT2A receptor

Read paper

Condition Treated :

N/A; Healthy volunteers

Psychedelic Medicine :

LSD

Keywords

LSD, lysergic acid diethylamide, consciousness, default mode network, global brain connectivity, serotonin receptor

Safety and Efficacy of Lysergic Acid Diethylamide-Assisted Psychotherapy for Anxiety Associated With Life-threatening Diseases

Read paper

Condition Treated :

Life-threatening diseases

Psychedelic Medicine :

LSD

Keywords

LSD, lysergic acid diethylamide, lysergic acid diethylamide treatment, psychedelic treatment, anxiety, life-threatening disease, psychotherapy, end-of-life anxiety

LSD-assisted psychotherapy for anxiety associated with a life-threatening disease: A qualitative study of acute and sustained subjective effects

Read paper

Condition Treated :

Life-threatening diseases

Psychedelic Medicine :

LSD

Keywords

LSD, lysergic acid diethylamide, lysergic acid diethylamide treatment, psychedelic treatment, anxiety, life-threatening disease, psychotherapy

Safety, tolerability, pharmacokinetics, and pharmacodynamics of low dose lysergic acid diethylamide (LSD) in healthy older volunteers

Read paper

Condition Treated :

N/A; Healthy volunteers

Psychedelic Medicine :

LSD

Keywords

LSD, lysergic acid diethylamide, lysergic acid diethylamide treatment, psychedelic treatment, neurodegenerative disease, Alzheimer’s Disease, micro-dosing, neuroinflammation

LSD Acutely Impairs Fear Recognition and Enhances Emotional Empathy and Sociality

Read paper

Condition Treated :

N/A; Healthy volunteers

Psychedelic Medicine :

LSD

Keywords

LSD, lysergic acid diethylamide, lysergic acid diethylamide treatment, psychedelic treatment, empathy, emotional processing

Ketamine for rapid reduction of suicidal thoughts in major depression: a midazolam-controlled randomized clinical trial

Read paper

Condition Treated :

Suicidal Ideation

Psychedelic Medicine :

Ketamine

Keywords

ketamine, ketamine treatment, psychedelic treatment, depression, major depressive disorder, major depression, suicidal ideation

Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: a randomized clinical trial

Read paper

Condition Treated :

Post-Traumatic Stress Disorder

Psychedelic Medicine :

Ketamine

Keywords

ketamine, ketamine treatment, psychedelic treatment, PTSD, post-traumatic stress disorder

Efficacy of intravenous ketamine treatment in anxious versus nonanxious unipolar treatment-resistant depression

Read paper

Condition Treated :

Depression

Psychedelic Medicine :

Ketamine

Keywords

ketamine, ketamine treatment, psychedelic treatment, depression, treatment-resistant depression, anxious depression, nonanxious depression, major depression, major depressive disorder

Rapid antidepressant effects of the psychedelic ayahuasca in treatment-resistant depression: a randomized placebo-controlled trial

Read paper

Condition Treated :

Depression

Psychedelic Medicine :

Ayahuasca

Keywords

ayahuasca, DMT, N,N-Dimethyltryptamine, psychedelic treatment, ayahuasca treatment, depression, major depressive disorder, treatment-resistant depression, major depression

Potential Use of Ayahuasca in Grief Therapy

Read paper

Condition Treated :

Prolonged Grief Disorder

Psychedelic Medicine :

Ayahuasca

Keywords

ayahuasca, DMT, N,N-Dimethyltryptamine, psychedelic treatment, ayahuasca treatment, grief, emotional numbness, life purpose/meaning, peer-support group, group therapy

Effects of ayahuasca on psychometric measures of anxiety, panic-like and hopelessness in Santo Daime members

Read paper

Condition Treated :

N/A; Healthy volunteers

Psychedelic Medicine :

Ayahuasca

Keywords

ayahuasca, DMT, N,N-Dimethyltryptamine, psychedelic treatment, ayahuasca treatment, anxiety, hopelessness, emotional states

Discontinuation of medications classified as reuptake inhibitors affects treatment response of MDMA-assisted psychotherapy

Read paper

Condition Treated :

Post-Traumatic Stress Disorder

Psychedelic Medicine :

MDMA

Keywords

MDMA, PTSD, post-traumatic stress disorder, 3,4-Methylenedioxymethamphetamine, psychotherapy, MDMA treatment, psychedelic treatment, treatment-resistant, anti-depressant

Durability of improvement in post-traumatic stress disorder symptoms and absence of harmful effects or drug dependency after 3,4-methylenedioxymethamphetamine-assisted psychotherapy: a prospective long term follow-up study

Read paper

Condition Treated :

Post-Traumatic Stress Disorder

Psychedelic Medicine :

MDMA

Keywords

MDMA, PTSD, post-traumatic stress disorder, 3,4-Methylenedioxymethamphetamine, psychotherapy, MDMA treatment, psychedelic treatment, treatment-resistant, long-term study

The safety and efficacy of 3,4-methylenedioxymethamphetamine- assisted psychotherapy in subjects with chronic, treatment-resistant posttraumatic stress disorder: the first randomized controlled pilot study

Read paper

Condition Treated :

Post-Traumatic Stress Disorder

Psychedelic Medicine :

MDMA

Keywords

MDMA, PTSD, post-traumatic stress disorder, 3,4-Methylenedioxymethamphetamine, psychotherapy, MDMA treatment, psychedelic treatment, treatment-resistant

3,4-Methylenedioxymethamphetamine-assisted psychotherapy for treatment of chronic posttraumatic stress disorder: A randomized phase 2 controlled trial

Read paper

Condition Treated :

Post-Traumatic Stress Disorder

Psychedelic Medicine :

MDMA

Keywords

MDMA, PTSD, post-traumatic stress disorder, 3,4-Methylenedioxymethamphetamine, psychotherapy, MDMA treatment, psychedelic treatment, emotional dysregulation, breakthrough therapy, amygdala, depression

MDMA-assisted therapy: A new treatment model for social anxiety in autistic adults

Read paper

Condition Treated :

Autism

Psychedelic Medicine :

MDMA

Keywords

MDMA, autism, social anxiety, empathy, MDMA treatment, psychedelic treatment, 3,4-Methylenedioxymethamphetamine, psychotherapy

Acute iboga alkaloid effects on extracellular serotonin (5-HT) levels in nucleus accumbens and striatum in rats

Read paper

Condition Treated :

N/A; Healthy volunteers

Psychedelic Medicine :

Ibogaine

Keywords

ibogaine, noribogaine, 18-MC, 18-methoxycoronaridine, serotonergic system, hallucinogen, addiction, reward pathway

Effects of 18-methoxycoronaridine on acute signs of morphine withdrawal in rats

Read paper

Condition Treated :

Opioid Use Disorder

Psychedelic Medicine :

Ibogaine

Keywords

ibogaine, iboga alkaloids, iboga compounds, animal study, morphine, opioid, substance use, substance use disorder, 18-MC, 18-methoxycoronaridine

18-Methoxycoronaridine, a non-toxic iboga alkaloid congener: effects on morphine and cocaine self-administration and on mesolimbic dopamine release in rats

Read paper

Condition Treated :

Substance Use Disorder

Psychedelic Medicine :

Ibogaine

Keywords

ibogaine, iboga alkaloids, iboga compounds, animal study, morphine, cocaine, stimulant, substance use, substance use disorder, 18-MC, 18-methoxycoronaridine

Effects of iboga alkaloids on morphine and cocaine self-administration in rats: relationship to tremorigenic effects and to effects on dopamine release in nucleus accumbens and striatum

Read paper

Condition Treated :

Substance Use Disorder

Psychedelic Medicine :

Ibogaine

Keywords

ibogaine, iboga alkaloids, iboga compounds, animal study, morphine, cocaine, stimulant, substance use, substance use disorder

Iboga compounds reverse the behavioural disinhibiting and corticosterone effects of acute methamphetamine: Implications for their anti-addictive properties

Read paper

Condition Treated :

Methamphetamine Use

Psychedelic Medicine :

Ibogaine

Keywords

ibogaine, 18-MC, iboga compounds, anxiety, animal study, elevated plus maze, methamphetamine, stimulant, substance use, substance use disorder

Ibogaine: complex pharmacokinetics, concerns for safety, and preliminary efficacy measures

Read paper

Condition Treated :

Substance Use Disorder

Psychedelic Medicine :

Ibogaine

Keywords

ibogaine, ibogaine treatment, substance use, opiate use, cocaine use, addiction, noribogaine

18-Methoxycoronardine attenuates nicotine-induced dopamine release and nicotine preferences in rats

Read paper

Condition Treated :

Nicotine Use

Psychedelic Medicine :

Ibogaine

Keywords

ibogaine, iboga alkaloid, 18-MC, 18-methoxycoronaridine, nicotine use disorder, ibogaine treatment, 18-MC treatment

Enhancement of morphine antinociception by ibogaine and noribogaine in morphine-tolerant mice

Read paper

Condition Treated :

Morphine Use

Psychedelic Medicine :

Ibogaine

Keywords

ibogaine, antinociception, pain-relief, morphine use, noribogaine

Plants and the central nervous system

Read paper

Condition Treated :

Substance Use Disorder

Psychedelic Medicine :

Ibogaine

Keywords

ibogaine, substance use disorder, iboga

Plant derivatives in the treatment of alcohol dependency

Read paper

Condition Treated :

Alcohol Use Disorder

Psychedelic Medicine :

Ibogaine

Keywords

ibogaine, iboga alkaloid, 18-MC, 18-methoxycoronaridine, alcohol use disorder, plant derivatives, plant medicine

Novel iboga alkaloid congeners block nicotinic receptors and reduce drug self-administration

Read paper

Condition Treated :

Substance Use Disorder

Psychedelic Medicine :

Ibogaine

Keywords

18-MC, 18-methoxycoronaridine, drug self-administration, nicotinic receptor, animal model, ibogaine

18-Methoxycoronaridine acts in the medial habenula and/or interpeduncular nucleus to decrease morphine self-administration in rats

Read paper

Condition Treated :

Morphine Use

Psychedelic Medicine :

Ibogaine

Keywords

18-MC, 18-methoxycoronaridine, drug self-administration, reward pathway, habenulo-interpeduncular pathway, nicotinic receptor

Ibogaine, an anti-addictive drug: pharmacology and time to go further in development. A narrative review

Read paper

Condition Treated :

Substance Use Disorder

Psychedelic Medicine :

Ibogaine

Keywords

iboga, ibogaine, opioid use disorder, substance use disorder, ibogaine therapy, ibogaine treatment, cocaine use disorder, alcohol use disorder

Brain regions mediating α3β4 nicotinic antagonist effects of 18-MC on methamphetamine and sucrose self-administration

Read paper

Condition Treated :

Substance Use Disorder

Psychedelic Medicine :

Ibogaine

Keywords

18-MC, 18-methoxycoronaridine, drug self-administration, reward pathway, dopaminergic-mesolimbic activity, nicotinic receptor

Pharmacotherapy of Addictive Disorders

Read paper

Condition Treated :

Substance Use Disorder

Psychedelic Medicine :

Ibogaine

Keywords

ibogaine, iboga, ibogaine treatment, ibogaine therapy, iboga alkaloids, substance use disorder, addiction

Anti-addiction drug ibogaine inhibits hERG channels: a cardiac arrhythmia risk

Read paper

Condition Treated :

N/A; Healthy volunteers

Psychedelic Medicine :

Ibogaine

Keywords

ibogaine, iboga

Phytotherapy of alcoholism

Read paper

Condition Treated :

Alcohol Use Disorder

Psychedelic Medicine :

Ibogaine

Keywords

ibogaine, ibogaine therapy, alcohol use disorder, alcohol dependency

Ex vivo effects of ibogaine on the activity of antioxidative enzymes in human erythrocytes

Read paper

Condition Treated :

N/A; Healthy volunteers

Psychedelic Medicine :

Ibogaine

Keywords

ibogaine, oxidative stress, antioxidants, erythrocytes

Functional neurotoxicity evaluation of noribogaine using video-EEG in cynomolgus monkeys

Read paper

Condition Treated :

Seizure activity

Psychedelic Medicine :

Ibogaine

Keywords

noribogaine, opioid use disorder, noribogaine treatment, seizure, seizure risk, electroencephalograph, EEG

Remission of severe opioid use disorder with ibogaine: a case report

Read paper

Condition Treated :

Opioid Use Disorder

Psychedelic Medicine :

Ibogaine

Keywords

iboga, ibogaine, opioid use disorder, substance use disorder, ibogaine therapy, ibogaine treatment

Ibogaine - structure, influence on human body, clinical relevance

Read paper

Condition Treated :

Opioid Use Disorder

Psychedelic Medicine :

Ibogaine

Keywords

iboga, ibogaine, opioid use disorder, nicotine use, alcohol use, cocaine use, methamphetamine use, substance use disorder, iboga treatment, ibogaine treatment

An overview of anti-diabetic plants used in Gabon: Pharmacology and toxicology

Read paper

Condition Treated :

Diabetes Mellitus

Psychedelic Medicine :

Ibogaine

Keywords

iboga, diabetes, iboga treatment, insulin stimulation

Examination of the Phenomenology of the Ibogaine Treatment Experience: Role of Altered States of Consciousness and Psychedelic Experiences

Read paper

Condition Treated :

Opioid Use Disorder

Psychedelic Medicine :

Ibogaine

Keywords

ibogaine, ibogaine treatment, oneiric, oneirogen, opioid use disorder, alcohol use disorder, anxiety, chronic pain, spiritual enhancement, visions, altered states of consciousness

A phenomenological analysis of the subjective experience elicited by ibogaine in the context of a drug dependence treatment

Read paper

Condition Treated :

Opioid Use Disorder

Psychedelic Medicine :

Ibogaine

Keywords

ibogaine, ibogaine treatment, oneiric, oneirogen

Changes in Withdrawal and Craving Scores in Participants Undergoing Opioid Detoxification Utilizing Ibogaine

Read paper

Condition Treated :

Opioid Use Disorder

Psychedelic Medicine :

Ibogaine

Keywords

ibogaine, opioid dependence, substance use disorder, opioid use disorder, psychedelic treatment, ibogaine treatment, opioid withdrawal

Cytochrome P450 and O-methyltransferase catalyze the final steps in the biosynthesis of the anti-addictive alkaloid ibogaine from Tabernanthe iboga

Read paper

Condition Treated :

N/A; Healthy volunteers

Psychedelic Medicine :

Ibogaine

Keywords

iboga, ibogaine, biosynthesis, anti-addictive alkaloid, substance use disorder, substance use dependency

DARK Classics in Chemical Neuroscience: Ibogaine

Read paper

Condition Treated :

Substance Use Disorder

Psychedelic Medicine :

Ibogaine

Keywords

18-methoxycoronaridine (18-MC), ibogaine analog, iboga treatment, substance use disorder, substance use dependency

Phytochemical characterization of Tabernanthe iboga root bark and its effects on dysfunctional metabolism and cognitive performance in high-fat-fed C57BL/6J mice

Read paper

Condition Treated :

Diabetes Mellitus

Psychedelic Medicine :

Ibogaine

Keywords

Induction of insulin secretion by an aqueous extract of Tabernanthe iboga Baill. (Apocynaceae) in rat pancreatic islets of Langerhans

Read paper

Condition Treated :

Diabetes Mellitus

Psychedelic Medicine :

Ibogaine

Keywords

iboga, diabetes mellitus, type II diabetes mellitus, iboga treatment, insulin stimulation

Ibogaine and Subjective Experience: Transformative States and Psychopharmacotherapy in the Treatment of Opioid Use Disorder

Read paper

Condition Treated :

Opioid Use Disorder

Psychedelic Medicine :

Ibogaine

Keywords

ibogaine, opioid dependence, substance use disorder, opioid use disorder, psychedelic treatment, ibogaine treatment, opioid withdrawal

Novel treatment of opioid use disorder using ibogaine and iboga in two adults

Read paper

Condition Treated :

Opioid Use Disorder

Psychedelic Medicine :

Ibogaine

There is variation in the population that uses opioids, thus there should be a variety of treatment options for those using opioids
Over a treatment period of 6 days, this patient did not experience opioid withdrawal symptoms or any chronic pain after day 4 of treatment, and has abstained from any opioid use for 3 years following the study

Not only did opioid withdrawal symptoms and opioid use dissipate, the patient was able to process emotions of guilt, shame, and remorse that had accumulated throughout their life; the patient was able to move on in life and from opioid use experience “without any boundaries”
This patient found ibogaine to be transformative beyond treating his addiction alone: the patient was able to become more in awe of beauty of the world, converted to a spiritual Muslim (from Orthodox Muslim), experiencing God as a realization (versus a textbook concept), and is more happy and at peace in life

Opioid agonist therapies often just mask withdrawal symptoms for users; they don’t help to address the underlying reasons people want to use
Over 8 days of iboga treatment, another patient (using 500mg fentanyl + 600mg morphine) was able to reduce her sustained release oral morphine (SROM) from 600mg to 200mg and stopped using all illicit opioids; 85% reduction in total opioid use

After the final iboga admission, this patient stopped all opioid medications and has abstained from any use of opioids, cocaine, amphetamines, and alcohol for 2 years

Both patients found improved mood, engagement in everyday activities, and improved relationships following ibogaine treatment; due to: gained insight into their situations, increased self-awareness, positivity, and determination
Patient 2 also struggled with anxiety and depression before treatment with ibogaine, and following such treatment, these conditions have largely resolved as well
The ibogaine treatment was effective for both: a patient who did not try other therapies for opioid use disorder (was resistant to try) and a patient who tried many other therapies
Ibogaine can be administered in single or multiple treatment sessions over a short time period (rapid detox)

Short treatment period allows the patient to be free of constraints; is better able to contribute to the workforce and engage in personal interests → economic and functional advantage

The psychedelic experience from ibogaine allows insight, aligns the patient’s values, permits connectedness to higher powers, introspection, personal growth, and to realize peace and happiness

This experience is thought to result in neural network reorganization and interruption of the neural pathways underlying substance use disorder

One cautionary note with ibogaine treatment, is that it can cause cardiac arrhythmias, thus should be closely monitored if the patient has heart conditions (a small, test dose of ibogaine is typically administered prior to full flood dosages to account for this cautionary measure)
Neither patient expressed any desire to experience ibogaine treatment again (ibogaine is non-addictive)

Keywords

ibogaine, opioid dependence, substance use disorder, opioid use disorder, psychedelic treatment, ibogaine treatment, opioid withdrawal, pharmacological mechanism

Treatment of opioid use disorder with ibogaine: detoxification and drug use outcomes

Read paper

Condition Treated :

Opioid Use Disorder

Psychedelic Medicine :

Ibogaine

Keywords

ibogaine, opioid dependence, substance use disorder, opioid use disorder, psychedelic treatment, ibogaine treatment, opioid withdrawal, pharmacological mechanism

Ibogaine treatment outcomes for opioid dependence from a twelve-month follow-up observational study

Read paper

Condition Treated :

Opioid Use Disorder

Psychedelic Medicine :

Ibogaine

Keywords

ibogaine, opioid dependence, substance use disorder, opioid use disorder, psychedelic treatment, ibogaine treatment, opioid withdrawal, pharmacological mechanism

Exploratory Controlled Study of the Migraine-Suppressing Effects of Psilocybin

Read paper

Condition Treated :

Migraine

Psychedelic Medicine :

Psilocybin

Keywords

psilocybin, migraine, headache disorder, psychedelic treatment, psilocybin treatment, psychotherapy

Pilot Study of the 5-HT2AR Agonist Psilocybin in the Treatment of Tobacco Addiction

Read paper

Condition Treated :

Tobacco Dependence

Psychedelic Medicine :

Psilocybin

Keywords

tobacco use, tobacco dependency, nicotine dependency, nicotine use, psilocybin, psilocybin-assisted psychotherapy, psilocybin treatment

Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer

Read paper

Condition Treated :

Anxiety

Psychedelic Medicine :

Psilocybin

Keywords

anxiety, cancer, advanced-stage cancer, treatment-resistant, psilocybin, psilocybin-assisted treatment

Psilocybin-assisted treatment for alcohol dependence: A proof-of-concept study

Read paper

Condition Treated :

Alcohol Use Disorder

Psychedelic Medicine :

Psilocybin

Keywords

psilocybin, alcohol dependence, alcohol use disorder, substance use disorder, psychedelic treatment, psilocybin treatment, psychotherapy, addiction treatment, alcoholism

Increased amygdala responses to emotional faces after psilocybin for treatment-resistant depression

Read paper

Condition Treated :

Depression

Psychedelic Medicine :

Psilocybin

Keywords

psilocybin, depression, treatment-resistant depression, major depression, psychedelic treatment, psilocybin treatment, amygdala, emotional dysregulation, psychotherapy, emotional processing

Treatment of Acute Opioid Withdrawal with Ibogaine

Read paper

Condition Treated :

Opioid Use Disorder

Psychedelic Medicine :

Ibogaine

Keywords

ibogaine, opioid dependence, substance use disorder, opioid use disorder, psychedelic treatment, ibogaine treatment, opioid withdrawal, pharmacological mechanism

Characterization and prediction of acute and sustained response to psychedelic psilocybin in a mindfulness group retreat

Read paper

Condition Treated :

N/A; Healthy volunteers

Psychedelic Medicine :

Psilocybin

Keywords

psilocybin, meditation, mindfulness, self-consciousness, psychedelic treatment, psilocybin treatment, mindfulness retreat, meditation retreat, group retreat

Psychedelic Research Findings

Filters

The Patient’s Perspective on the Effects of Intranasal Esketamine in Treatment-Resistant Depression

Esketamine Nasal Spray versus Quetiapine for Treatment-Resistant Depression

Psilocybin-assisted therapy for depression: A systematic review and meta-analysis

Therapeutic Potential of Psilocybin for Treating Psychological Distress among Survivors of Adverse Childhood Experiences: Evidence on Acceptability and Potential Efficacy of Psilocybin Use

Longitudinal associations between psychedelic use and meditation practices in the United States and the United Kingdom

Adults who microdose psychedelics report health related motivations and lower levels of anxiety and depression compared to non-microdosers

Vitamin C, Pain and Opioid Use Disorder

Medical Cannabis for Pediatric Moderate to Severe Complex Motor Disorders

Evaluation of the effects of CBD hemp extract on opioid use and quality of life indicators in chronic pain patients: a prospective cohort study

The Effectiveness of Topical Cannabidiol Oil in Symptomatic Relief of Peripheral Neuropathy of the Lower Extremities

Salvia divinorum: from recreational hallucinogenic use to analgesic and anti-inflammatory action

Antidepressant Effects of the Herb Salvia Divinorum: A Case Report

The subjective experience of acute, experimentally-induced Salvia divinorum inebriation

The Appeal of Peyote (Lophophora Williamsii) as a Medicine

Psychological and Cognitive Effects of Long-Term Peyote Use Among Native Americans

The non-hallucinogen 2-bromo-lysergic acid diethylamide as preventative treatment for cluster headache: an open, non-randomized case series

Alterations in responses to LSD in humans associated with chronic administration of tricyclic antidepressants, monoamine oxidase inhibitors or lithium

The Fabric of Meaning and Subjective Effects in LSD-Induced States Depend on Serotonin 2A Receptor Activation

Role of the 5-HT 2A Receptor in Self- and Other-Initiated Social Interaction in Lysergic Acid Diethylamide-Induced States: A Pharmacological fMRI Study

Changes in global and thalamic brain connectivity in LSD-induced altered states of consciousness are attributable to the 5-HT2A receptor

Safety and Efficacy of Lysergic Acid Diethylamide-Assisted Psychotherapy for Anxiety Associated With Life-threatening Diseases

LSD-assisted psychotherapy for anxiety associated with a life-threatening disease: A qualitative study of acute and sustained subjective effects

Safety, tolerability, pharmacokinetics, and pharmacodynamics of low dose lysergic acid diethylamide (LSD) in healthy older volunteers

LSD Acutely Impairs Fear Recognition and Enhances Emotional Empathy and Sociality

Ketamine for rapid reduction of suicidal thoughts in major depression: a midazolam-controlled randomized clinical trial

Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: a randomized clinical trial

Efficacy of intravenous ketamine treatment in anxious versus nonanxious unipolar treatment-resistant depression

Rapid antidepressant effects of the psychedelic ayahuasca in treatment-resistant depression: a randomized placebo-controlled trial

Potential Use of Ayahuasca in Grief Therapy

Effects of ayahuasca on psychometric measures of anxiety, panic-like and hopelessness in Santo Daime members

Discontinuation of medications classified as reuptake inhibitors affects treatment response of MDMA-assisted psychotherapy

Durability of improvement in post-traumatic stress disorder symptoms and absence of harmful effects or drug dependency after 3,4-methylenedioxymethamphetamine-assisted psychotherapy: a prospective long term follow-up study

The safety and efficacy of 3,4-methylenedioxymethamphetamine- assisted psychotherapy in subjects with chronic, treatment-resistant posttraumatic stress disorder: the first randomized controlled pilot study

3,4-Methylenedioxymethamphetamine-assisted psychotherapy for treatment of chronic posttraumatic stress disorder: A randomized phase 2 controlled trial

MDMA-assisted therapy: A new treatment model for social anxiety in autistic adults

Acute iboga alkaloid effects on extracellular serotonin (5-HT) levels in nucleus accumbens and striatum in rats

Effects of 18-methoxycoronaridine on acute signs of morphine withdrawal in rats

18-Methoxycoronaridine, a non-toxic iboga alkaloid congener: effects on morphine and cocaine self-administration and on mesolimbic dopamine release in rats

Effects of iboga alkaloids on morphine and cocaine self-administration in rats: relationship to tremorigenic effects and to effects on dopamine release in nucleus accumbens and striatum

Iboga compounds reverse the behavioural disinhibiting and corticosterone effects of acute methamphetamine: Implications for their anti-addictive properties

Ibogaine: complex pharmacokinetics, concerns for safety, and preliminary efficacy measures

18-Methoxycoronardine attenuates nicotine-induced dopamine release and nicotine preferences in rats

Enhancement of morphine antinociception by ibogaine and noribogaine in morphine-tolerant mice

Plants and the central nervous system

Plant derivatives in the treatment of alcohol dependency

Novel iboga alkaloid congeners block nicotinic receptors and reduce drug self-administration

18-Methoxycoronaridine acts in the medial habenula and/or interpeduncular nucleus to decrease morphine self-administration in rats

Ibogaine, an anti-addictive drug: pharmacology and time to go further in development. A narrative review

Brain regions mediating α3β4 nicotinic antagonist effects of 18-MC on methamphetamine and sucrose self-administration

Pharmacotherapy of Addictive Disorders

Anti-addiction drug ibogaine inhibits hERG channels: a cardiac arrhythmia risk

Phytotherapy of alcoholism

Ex vivo effects of ibogaine on the activity of antioxidative enzymes in human erythrocytes

Functional neurotoxicity evaluation of noribogaine using video-EEG in cynomolgus monkeys

Remission of severe opioid use disorder with ibogaine: a case report

Ibogaine - structure, influence on human body, clinical relevance

An overview of anti-diabetic plants used in Gabon: Pharmacology and toxicology

Examination of the Phenomenology of the Ibogaine Treatment Experience: Role of Altered States of Consciousness and Psychedelic Experiences

A phenomenological analysis of the subjective experience elicited by ibogaine in the context of a drug dependence treatment

Changes in Withdrawal and Craving Scores in Participants Undergoing Opioid Detoxification Utilizing Ibogaine

Cytochrome P450 and O-methyltransferase catalyze the final steps in the biosynthesis of the anti-addictive alkaloid ibogaine from Tabernanthe iboga

DARK Classics in Chemical Neuroscience: Ibogaine

Phytochemical characterization of Tabernanthe iboga root bark and its effects on dysfunctional metabolism and cognitive performance in high-fat-fed C57BL/6J mice

Induction of insulin secretion by an aqueous extract of Tabernanthe iboga Baill. (Apocynaceae) in rat pancreatic islets of Langerhans

Ibogaine and Subjective Experience: Transformative States and Psychopharmacotherapy in the Treatment of Opioid Use Disorder

Novel treatment of opioid use disorder using ibogaine and iboga in two adults

Treatment of opioid use disorder with ibogaine: detoxification and drug use outcomes

Ibogaine treatment outcomes for opioid dependence from a twelve-month follow-up observational study

Exploratory Controlled Study of the Migraine-Suppressing Effects of Psilocybin

Pilot Study of the 5-HT2AR Agonist Psilocybin in the Treatment of Tobacco Addiction

Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer

Psilocybin-assisted treatment for alcohol dependence: A proof-of-concept study

Increased amygdala responses to emotional faces after psilocybin for treatment-resistant depression

Treatment of Acute Opioid Withdrawal with Ibogaine

Characterization and prediction of acute and sustained response to psychedelic psilocybin in a mindfulness group retreat

Want to find more research findings?

Check out Porta Sophia's global search tool